Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

RECRUITING

Novartis Investigative Site, Córdoba

RECRUITING

Novartis Investigative Site, Milan

RECRUITING

Novartis Investigative Site, Ranica

RECRUITING

Novartis Investigative Site, Kiel

RECRUITING

Novartis Investigative Site, Málaga

RECRUITING

Novartis Investigative Site, Toulouse

RECRUITING

Novartis Investigative Site, Bordeaux

RECRUITING

Novartis Investigative Site, Mersin

RECRUITING

Novartis Investigative Site, Izmir

RECRUITING

Novartis Investigative Site, Tours

RECRUITING

Novartis Investigative Site, Seville

RECRUITING

Novartis Investigative Site, Kocaeli

RECRUITING

Novartis Investigative Site, Essen

RECRUITING

Novartis Investigative Site, Paris

RECRUITING

Novartis Investigative Site, Paris

RECRUITING

Novartis Investigative Site, Rouen

RECRUITING

Novartis Investigative Site, Beijing

RECRUITING

Novartis Investigative Site, Beijing

RECRUITING

Novartis Investigative Site, Shanghai

RECRUITING

Novartis Investigative Site, Nanjing

RECRUITING

Novartis Investigative Site, Roma

RECRUITING

Novartis Investigative Site, Iruma-gun

RECRUITING

Novartis Investigative Site, Bunkyo Ku

RECRUITING

Novartis Investigative Site, Barcelona

RECRUITING

Novartis Investigative Site, Ankara

RECRUITING

Novartis Investigative Site, Glasgow

RECRUITING

Novartis Investigative Site, London

RECRUITING

Novartis Investigative Site, Newcastle upon Tyne